{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:03:07Z","timestamp":1787022187537,"version":"build-2736575974"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Major Project for the Prevention and Control of Cancer, Cardiovascular and Cerebrovascular Diseases, Respiratory and Metabolic Diseases","award":["2024ZD0528103"],"award-info":[{"award-number":["2024ZD0528103"]}]},{"DOI":"10.13039\/501100012248","name":"Collaborative Innovation Center for Modern Science and Technology and Industrial Development of Jiangxi Traditional Medicine","doi-asserted-by":"publisher","award":["M-2023219"],"award-info":[{"award-number":["M-2023219"]}],"id":[{"id":"10.13039\/501100012248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The U.S. Food and Drug Administration (FDA) approved intravenous edaravone for the treatment of amyotrophic lateral sclerosis (ALS) in 2017, followed by the approval of the oral formulation in 2022. This study aims to utilize the FDA#39;s Adverse Event Reporting System (FAERS) to investigate the spectrum and timing of adverse events (AEs) associated with edaravone administration, employing repeatability analysis, the Reporting Odds Ratio (ROR) approach, Weibull distribution, and stratification methods. The investigation focuses on data collected from the first quarter of 2017 through the fourth quarter of 2024, aiming to identify adverse event signals and their temporal patterns related to both intravenous and oral edaravone administration. In total, 3,262 records of edaravone-related adverse reactions were identified; among these, 1,534 incidents were associated with intravenous administration, while 453 incidents pertained to oral administration. The analysis revealed distinct adverse reaction profiles for the two routes of administration. Notably, the spectrum of adverse reactions resulting from oral administration predominantly involved the respiratory system, digestive system, and skin damage. In contrast, intravenous administration was more frequently linked to complications associated with invasive procedures and local tissue damage. Furthermore, the timing of adverse reactions exhibited significant variability between the two routes. Weibull distribution analysis indicated that the median onset time for adverse reactions following intravenous administration was 35 days, whereas for oral administration, it was 27 days. Both analytical approaches identified early failure signals, suggesting that the risk of adverse events diminishes over time.<\/jats:p>","DOI":"10.1371\/journal.pone.0346797","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:29:05Z","timestamp":1776101345000},"page":"e0346797","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system"],"prefix":"10.1371","volume":"21","author":[{"given":"Deye","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zecheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-3058","authenticated-orcid":true,"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"8","key":"pone.0346797.ref001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/aps.2015.31","article-title":"The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats","volume":"36","author":"K Hua","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"pone.0346797.ref002","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"MK Jaiswal","year":"2019","journal-title":"Med Res Rev"},{"issue":"10","key":"pone.0346797.ref003","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/01.STR.0000182241.07096.06","article-title":"Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain","volume":"36","author":"N Zhang","year":"2005","journal-title":"Stroke"},{"issue":"10","key":"pone.0346797.ref004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737175.2023.2251687","article-title":"Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis","volume":"23","author":"GL Pattee","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"pone.0346797.ref005","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21678421.2018.1517179","article-title":"Is edaravone harmful? (A placebo is not a control)","volume":"19","author":"J Turnbull","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"pone.0346797.ref006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mus.27768","article-title":"Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48\u2009weeks of treatment","volume":"67","author":"A Genge","year":"2023","journal-title":"Muscle Nerve"},{"issue":"2","key":"pone.0346797.ref007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis","volume":"79","author":"S Witzel","year":"2022","journal-title":"JAMA Neurol"},{"key":"pone.0346797.ref008","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/21678421.2019.1645858","article-title":"Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch","volume":"20","author":"C Jackson","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"pone.0346797.ref009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2019.06.006","article-title":"Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy","volume":"404","author":"A Fortuna","year":"2019","journal-title":"J Neurol Sci"},{"issue":"1","key":"pone.0346797.ref010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10072-019-04055-3","article-title":"Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients","volume":"41","author":"J-M Park","year":"2020","journal-title":"Neurol Sci"},{"issue":"12","key":"pone.0346797.ref011","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.clinthera.2023.09.025","article-title":"Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis","volume":"45","author":"H Shimizu","year":"2023","journal-title":"Clin Ther"},{"issue":"3","key":"pone.0346797.ref012","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000001742","article-title":"Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis","volume":"31","author":"P Singh","year":"2024","journal-title":"Am J Ther"},{"issue":"2","key":"pone.0346797.ref013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10072-018-3653-2","article-title":"Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis","volume":"40","author":"L Luo","year":"2019","journal-title":"Neurol Sci"},{"key":"pone.0346797.ref014","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"C Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"pone.0346797.ref015","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"L Meng","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"6","key":"pone.0346797.ref016","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"J-L Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0346797.ref017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40264-017-0611-5","article-title":"Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System","volume":"41","author":"J Min","year":"2018","journal-title":"Drug Saf"},{"issue":"4","key":"pone.0346797.ref018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Y Shu","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0346797.ref019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system","volume":"20","author":"BM Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0346797.ref020","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0346797.ref021","doi-asserted-by":"crossref","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Y Shu","year":"2022","journal-title":"Front Public Health"},{"issue":"4","key":"pone.0346797.ref022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/jnnp-2016-314093","article-title":"C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis","volume":"88","author":"J Rooney","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"pone.0346797.ref023","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10654-018-0392-x","article-title":"Age-specific ALS incidence: a dose-response meta-analysis","volume":"33","author":"B Marin","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"46","key":"pone.0346797.ref024","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.15585\/mmwr.mm6746a1","article-title":"Prevalence of amyotrophic lateral sclerosis - United States, 2015","volume":"67","author":"P Mehta","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"pone.0346797.ref025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpdd.1175","article-title":"Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study","volume":"12","author":"H Shimizu","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"pone.0346797.ref026","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"P Masrori","year":"2020","journal-title":"Eur J Neurol"},{"issue":"2","key":"pone.0346797.ref027","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.chest.2018.06.035","article-title":"Respiratory Failure in Amyotrophic Lateral Sclerosis","volume":"155","author":"S Niedermeyer","year":"2019","journal-title":"Chest"},{"issue":"11","key":"pone.0346797.ref028","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1373\/clinchem.2009.128397","article-title":"Cystatin C and cardiovascular risk","volume":"55","author":"N Taglieri","year":"2009","journal-title":"Clin Chem"},{"issue":"8","key":"pone.0346797.ref029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039366","article-title":"Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis","volume":"10","author":"L Feng","year":"2020","journal-title":"BMJ Open"},{"issue":"7","key":"pone.0346797.ref030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2176\/nmc.48.292","article-title":"Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism","volume":"48","author":"M Mishina","year":"2008","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"11","key":"pone.0346797.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/v13112301","article-title":"TDP-43 and HERV-K Envelope-Specific Immunogenic Epitopes Are Recognized in ALS Patients","volume":"13","author":"ER Simula","year":"2021","journal-title":"Viruses"},{"key":"pone.0346797.ref032","doi-asserted-by":"crossref","first-page":"1753466621992735","DOI":"10.1177\/1753466621992735","article-title":"Percutaneous endoscopic gastrostomy feeding effects in patients with neurogenic dysphagia and recurrent pneumonia","volume":"15","author":"JH Lee","year":"2021","journal-title":"Ther Adv Respir Dis"},{"issue":"26","key":"pone.0346797.ref033","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.3748\/wjg.v19.i26.4172","article-title":"Single endoscopist-performed percutaneous endoscopic gastrostomy tube placement","volume":"19","author":"A Erdogan","year":"2013","journal-title":"World J Gastroenterol"},{"key":"pone.0346797.ref034","first-page":"3402753","article-title":"Evidence-Based Research Strategy of Traditional Chinese Medicine for Amyotrophic Lateral Sclerosis","volume":"2021","author":"H Pan","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"pone.0346797.ref035","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.clinthera.2020.06.020","article-title":"An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment","volume":"42","author":"Y Nakamaru","year":"2020","journal-title":"Clin Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:29:10Z","timestamp":1776101350000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346797"}},"subtitle":[],"editor":[{"given":"Tariq","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346797","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}